Adenovirus infection is a common viral illness that usually affects the airways, eyes, or digestive system. While most people recover with simple rest and care at home, understanding treatment options—including those being explored in research—can help patients and families make informed choices, especially in more serious cases.

Fighting the Virus: What Treatment Aims to Achieve

When someone catches an adenovirus, the main goal of treatment is to help the body manage symptoms while the immune system does its work. Most adenovirus infections clear up on their own within a few days to two weeks, as the body’s natural defenses recognize and eliminate the virus. Treatment focuses on keeping the person comfortable during this time, preventing complications, and ensuring they stay hydrated and rested.^[1][2]

The approach to treating adenovirus depends heavily on several factors. The person’s age matters considerably—young children under five and elderly individuals tend to experience more severe symptoms. The part of the body affected also influences treatment decisions, since respiratory infections are handled differently than digestive tract problems or eye infections. People with weakened immune systems, including those who have received organ transplants or are undergoing cancer treatment, may need more intensive care and monitoring.^[1][8]

There are established ways to manage adenovirus that doctors use every day, based on decades of clinical experience. At the same time, researchers are investigating new antiviral medications and therapies in clinical trials, particularly for patients who face serious complications or have compromised immune systems. These ongoing studies aim to find treatments that can directly fight the virus, rather than just easing symptoms.

Standard Care: How Doctors Currently Treat Adenovirus

Currently, there are no approved antiviral medicines specifically designed to fight adenovirus infections in the general population. This means that standard treatment relies on what doctors call supportive care—helping the body through the illness while symptoms run their course.^[2][11]

Rest is one of the most important recommendations. The body needs energy to fight off the infection, and staying home from work or school also helps prevent spreading the virus to others. Isolation during the illness is particularly important because adenoviruses are highly contagious and can spread through coughs, sneezes, close contact, and contaminated surfaces.^[1]

Staying well-hydrated is another cornerstone of treatment. Fever, which is common with adenovirus, can lead to fluid loss through sweating. If the infection affects the digestive system and causes vomiting or diarrhea, the risk of dehydration—when the body loses more fluids than it takes in—becomes even greater. Drinking plenty of water and clear fluids helps replace what’s lost and supports the body’s healing processes.^[1][7]

For fever, headache, and body aches, over-the-counter pain relievers can provide relief. Adults and older children can take acetaminophen (also known as paracetamol) or ibuprofen to reduce fever and ease discomfort. However, aspirin should never be given to children under 12 years old who have viral infections, as it can cause a rare but serious condition called Reye’s syndrome, which affects the liver and brain.^[1][24]

When respiratory symptoms like nasal congestion and sore throat are troublesome, simple remedies can help. Humidifiers add moisture to the air, which can soothe irritated airways and make breathing more comfortable. Saline nasal drops can help clear a blocked nose, especially in young children who cannot blow their noses effectively. Throat lozenges or cough drops may ease throat pain in older children and adults, though these should not be given to very young children due to choking risk.^[1][7]

For patients with asthma, adenovirus infections can trigger breathing difficulties. In these cases, doctors may prescribe bronchodilators—medications delivered through inhalers that help open up the airways and make breathing easier.^[1]

Eye infections caused by adenovirus, such as pink eye (conjunctivitis), may be treated with antibiotic eye drops or ointments. While antibiotics don’t kill viruses, they can prevent secondary bacterial infections from taking hold in already irritated eyes.^[1]

When complications arise, such as pneumonia or middle ear infections, additional treatments become necessary. Pneumonia patients may require hospital admission for oxygen support, intravenous fluids to maintain hydration, and sometimes antibiotics if bacterial infections complicate the viral illness. Ear infections also typically respond to antibiotics along with pain management.^[1][8]

The duration of standard supportive treatment varies depending on the infection’s severity. Mild infections usually resolve within three to five days, though some symptoms like cough may linger for a couple of weeks. More severe infections, particularly in high-risk patients, may require longer recovery periods.^[1][4]

Side effects from supportive care treatments are generally minimal. Over-the-counter fever reducers, when used as directed, are safe for most people. However, excessive use of ibuprofen can irritate the stomach, and too much acetaminophen can harm the liver. Eye drops may cause temporary stinging or blurred vision. Healthcare providers can help patients understand proper dosing and watch for any adverse reactions.^[2]

Exploring New Frontiers: Treatment in Clinical Trials

For people with weakened immune systems or severe adenovirus infections, researchers are investigating antiviral drugs and innovative therapies that go beyond symptom management. These studies are particularly important for patients who have undergone stem cell or organ transplants, as adenovirus can cause life-threatening disseminated disease in these individuals.^[8][12]

Cidofovir is an antiviral medication that has received the most attention in treating severe adenovirus infections, though it is not officially approved for this use. Cidofovir works by interfering with viral DNA replication, essentially blocking the virus from making copies of itself inside infected cells. In clinical practice, doctors have used cidofovir “off-label” (meaning for a purpose other than what it was originally approved for) to treat immunocompromised patients with dangerous adenovirus infections.^[8][12]

The typical dosing of cidofovir for adenovirus involves giving the drug intravenously, either at 1 milligram per kilogram of body weight three times weekly, or at a higher dose of 5 milligrams per kilogram once weekly. Treatment continues until laboratory tests show that adenovirus is no longer detectable in the blood on two consecutive samples tested by a method called polymerase chain reaction (PCR), which can detect tiny amounts of viral genetic material.^[12]

However, cidofovir comes with significant challenges. The drug can damage the kidneys, which is a serious concern requiring careful monitoring of kidney function throughout treatment. Additionally, cidofovir is expensive, making it a resource-intensive option reserved only for the most severe cases. Because of these limitations, researchers continue searching for safer and more effective alternatives.^[12][13]

Clinical trials have explored several other antiviral agents as potential treatments for adenovirus. Ribavirin, an antiviral drug used for other viral infections, has been tested, though results have been mixed. One challenge with ribavirin is that when given as an aerosol (breathed in as a mist), it can pose risks to healthcare workers who administer it. Ganciclovir and vidarabine, both antiviral medications, have also been studied, but these drugs appear to be primarily virostatic—meaning they stop the virus from multiplying rather than killing it outright. This can lead to the virus rebounding once treatment stops, and there’s also concern about the virus developing resistance to these medications.^[12][13]

Researchers have found that most existing antiviral drugs face a fundamental problem: they don’t completely eliminate adenovirus from the body. Recovery ultimately depends on the patient’s immune system regaining strength, particularly the restoration of T-cell immunity—a type of immune defense where specialized white blood cells directly attack virus-infected cells.^[15]

This understanding has led to innovative approaches in clinical trials. One promising strategy involves adoptive T-cell therapy, where researchers take immune cells from a donor, grow and train them in the laboratory to recognize and attack adenovirus, then infuse them back into the patient. Early studies suggest this approach might help patients whose own immune systems cannot mount an adequate response. These trials are still in relatively early phases, evaluating both safety and effectiveness.^[15]

Another experimental approach involves giving patients immunoglobulin, which contains antibodies collected from many healthy donors. The theory is that these antibodies might provide temporary immune support to help fight the virus. Some clinical protocols have used immunoglobulin at a dose of 500 milligrams per kilogram of body weight, given weekly for three weeks. However, evidence for this treatment’s effectiveness remains limited.^[12]

Scientists are also investigating completely new molecular targets for antiviral drugs. Recent research has focused on identifying compounds that interfere with specific proteins the virus needs to replicate. Some experimental molecules work by blocking viral entry into cells, while others target enzymes essential for viral DNA replication or assembly of new virus particles. These studies are primarily in Phase I (testing safety in small numbers of people) or Phase II (testing effectiveness and optimal dosing in larger groups) of clinical development.^[13]

Another area of active research involves drug repurposing—testing medications already approved for other conditions to see if they might work against adenovirus. This approach can potentially speed up the availability of new treatments, since these drugs have already been proven safe for human use. Researchers screen existing medications to identify those that might interfere with adenovirus replication or enhance the body’s antiviral defenses.^[13]

Some clinical trials are investigating combination therapy, using two or more drugs together. The rationale is similar to how HIV or hepatitis C is treated—attacking the virus through multiple mechanisms simultaneously might be more effective than any single drug alone and could prevent the virus from developing resistance. Preliminary results from such approaches are being gathered, though no specific combinations have yet been proven superior in large-scale trials.^[13]

For patients considering participation in clinical trials, researchers look for specific eligibility criteria. Transplant recipients experiencing adenovirus viremia (virus detectable in the blood), patients with disseminated disease affecting multiple organs, or those with severe pneumonia despite standard care may be candidates. Trials are conducted at major medical centers in the United States, Europe, and other regions. Interested patients can work with their transplant teams or infectious disease specialists to determine if any appropriate studies are enrolling.^[15]

Early results from some trials offer cautious optimism. In transplant patients treated with cidofovir when viral levels were still relatively low, mortality rates appeared lower than historical controls who received no antiviral therapy. T-cell therapy trials have shown that some patients achieve clearance of the virus after receiving virus-specific immune cells. However, all these approaches remain investigational, and more research is needed to establish which patients benefit most and what the optimal treatment protocols should be.^[15]

Prevention: A Vaccine Exists, But With Limited Access

While treatment research continues, prevention remains the best strategy. A live oral vaccine against adenovirus types 4 and 7 does exist, but it’s only approved for use in U.S. military personnel aged 17 to 50 years. The vaccine was developed because military recruits living in crowded barracks and training facilities experienced frequent outbreaks of severe respiratory illness caused by these adenovirus types.^[2][11]

The military vaccine has not been tested in the general public, children, pregnant women, or people with weakened immune systems. After vaccination, people shed live virus in their stool for up to 28 days, which means they could potentially spread the vaccine virus to others during this period. Because of safety concerns and the lack of studies outside the military population, this vaccine is not available to the general public.^[2][11]

For everyone else, prevention relies on simple but effective hygiene measures: frequent, thorough handwashing, especially after touching potentially contaminated surfaces; avoiding touching the eyes, nose, and mouth with unwashed hands; covering coughs and sneezes with a tissue or elbow; staying home when sick; and disinfecting commonly touched surfaces. Swimming pools should maintain adequate chlorine levels, as adenovirus can spread through contaminated water.^[2][11]

Most common treatment methods

• Supportive care
  • Rest and isolation from others to prevent virus spread
  • Drinking plenty of fluids to maintain hydration
  • Over-the-counter fever reducers like acetaminophen or ibuprofen (avoiding aspirin in children under 12)
  • Use of humidifiers or saline nasal drops for respiratory symptoms
  • Throat lozenges for sore throat relief
  • Duration typically ranges from a few days to two weeks
• Treatment for respiratory complications
  • Bronchodilator inhalers for patients with asthma
  • Hospital admission for severe pneumonia with oxygen therapy and intravenous fluids
  • Antibiotics if secondary bacterial infections develop
• Antiviral therapy (investigational)
  • Cidofovir given intravenously at 1 mg/kg three times weekly or 5 mg/kg weekly for severe infections in immunocompromised patients
  • Used off-label, not officially approved for adenovirus
  • Requires kidney function monitoring due to risk of toxicity
  • Treatment continues until virus undetectable in blood by PCR testing
  • Other antivirals like ribavirin, ganciclovir, and vidarabine studied with limited success
• Immune-based therapies (experimental)
  • Adoptive T-cell therapy using donor immune cells trained to attack adenovirus
  • Immunoglobulin infusions at 500 mg/kg weekly for three weeks in some protocols
  • Available primarily through clinical trials at specialized centers
• Symptom-specific treatments
  • Antibiotic eye drops or ointments for conjunctivitis to prevent secondary bacterial infection
  • Antibiotics for ear infections (otitis media)
  • Rehydration therapy for gastroenteritis with vomiting and diarrhea